Tonix Pharmaceuticals Holding CORP 8-K filings

Tonix Pharmaceuticals presented clinical data on TNX-102 SL for acute stress reaction and PTSD prevention, and preclinical data on a high-throughput wound healing assay at the 2024 Military Health System Research Symposium.

Tonix Pharmaceuticals has partnered with Bilthoven Biologicals to develop manufacturing processes for its TNX-801 mpox vaccine candidate, aiming for potential GMP manufacturing.

Tonix Pharmaceuticals has initiated a Phase 2 clinical trial for TNX-1300, a potential treatment for acute cocaine intoxication, with the first patient dosed.

Tonix Pharmaceuticals announced its second quarter 2024 financial results and provided updates on its pipeline, highlighting progress towards an NDA submission for TNX-102 SL for fibromyalgia.

Tonix Pharmaceuticals presented data from a Phase 3 trial showing that TNX-102 SL significantly improved pain and sleep quality in fibromyalgia patients.

Tonix Pharmaceuticals reported preliminary Q2 2024 results including a net loss of $77.3 million and received a notice from Nasdaq regarding non-compliance with minimum bid price requirements.

Tonix Pharmaceuticals has entered into a sales agreement to potentially sell up to $50 million of its common stock through an at-the-market offering.

Tonix Pharmaceuticals has been granted Fast Track designation by the FDA for its Tonmya drug, aimed at treating fibromyalgia, a chronic pain condition.

Tonix Pharmaceuticals expects to record a $50 million non-cash impairment charge in its Q2 2024 financials due to the decommissioning of its Advanced Development Center.

Tonix Pharmaceuticals is progressing its fibromyalgia treatment, Tonmya, towards FDA approval while also advancing its broad-spectrum antiviral program with a $34 million DoD contract.

Tonix Pharmaceuticals has successfully closed a public offering, raising approximately $4 million to support working capital and drug development efforts.

Tonix Pharmaceuticals has received positive feedback from the FDA regarding its Tonmya drug for fibromyalgia, confirming the data package is sufficient for NDA submission in the second half of 2024.

Tonix Pharmaceuticals has entered into a $34 million agreement with the U.S. Department of Defense to develop a broad-spectrum antiviral drug.

Tonix Pharmaceuticals has successfully closed a public offering, raising approximately $4 million through the sale of common stock and pre-funded warrants.

Tonix Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement after its share price closed above $1.00 for ten consecutive business days.

Tonix Pharmaceuticals has received positive feedback from the FDA regarding its Tonmya drug for fibromyalgia, moving closer to a potential NDA submission in the second half of 2024.

Tonix Pharmaceuticals filed an amendment to its previous 8-K report to correct an error in the legal opinion exhibit.

Tonix Pharmaceuticals has successfully closed a public offering, raising $4 million to support working capital, general corporate purposes, and the development of its Tonmya product candidate.

Tonix Pharmaceuticals has completed a key meeting with the FDA regarding its drug candidate Tonmya for fibromyalgia and is preparing for a New Drug Application submission.

Tonix Pharmaceuticals will implement a 1-for-32 reverse stock split effective June 10, 2024, to meet the NASDAQ's minimum bid price requirement.

Tonix Pharmaceuticals announced positive data from presentations at the American Transplant Congress 2024, highlighting the potential of TNX-1500 in preventing organ transplant rejection and treating autoimmune diseases.

Tonix Pharmaceuticals' Tonmya demonstrated significant improvements in fibromyalgia symptoms, including depression, in a Phase 3 trial, with an NDA submission targeted for the second half of 2024.

Tonix Pharmaceuticals reported encouraging results for its TNX-102 SL product in treating fatigue related to Long COVID and is initiating a trial for acute stress reaction following motor vehicle collisions.

Tonix Pharmaceuticals plans to reduce its workforce by 23 employees and decommission its Massachusetts facility by June 7, 2024, while also securing shareholder approval for a reverse stock split and warrant repricing.

Tonix Pharmaceuticals will present data on Tonmya (TNX-102 SL) for fibromyalgia and other programs at the American Society of Clinical Psychopharmacology Annual Meeting, with a New Drug Application (NDA) submission planned for the second half of 2024.

Tonix Pharmaceuticals reports a favorable market assessment for its fibromyalgia drug candidate, Tonmya, with a potential NDA submission in the second half of 2024.

Tonix Pharmaceuticals announced its first quarter 2024 financial results and provided updates on its pipeline, including plans to submit an NDA for Tonmya in the second half of 2024.

Tonix Pharmaceuticals reported its full year 2023 financial results and highlighted the progress of its fibromyalgia drug, Tonmya, towards potential FDA approval.

Tonix Pharmaceuticals has announced a registered direct offering expected to generate $4.4 million in gross proceeds through the sale of common stock and warrants.

Tonix Pharmaceuticals has been granted Rare Pediatric Disease Designation by the FDA for its TNX-2900 product candidate, intended to treat Prader-Willi syndrome in children and adolescents.